These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 21448811)
21. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Jain P; Anantharaman G; Gopalakrishnan M; Goyal A Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155 [TBL] [Abstract][Full Text] [Related]
22. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Son BK; Kim K; Kim ES; Yu SY Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697 [TBL] [Abstract][Full Text] [Related]
23. Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation. Lo Giudice G; Gismondi M; De Belvis V; Cian R; Tavolato M; Galan A Retina; 2009; 29(7):949-55. PubMed ID: 19584653 [TBL] [Abstract][Full Text] [Related]
24. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography]. Liu Y; Li L; Xu G; Wang W Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704 [TBL] [Abstract][Full Text] [Related]
25. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046 [TBL] [Abstract][Full Text] [Related]
26. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
27. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Sato T; Kishi S; Matsumoto H; Mukai R Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441 [TBL] [Abstract][Full Text] [Related]
28. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Ma J; Meng N; Xu X; Zhou F; Qu Y Acta Ophthalmol; 2014 Dec; 92(8):e594-601. PubMed ID: 25042260 [TBL] [Abstract][Full Text] [Related]
30. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551 [TBL] [Abstract][Full Text] [Related]
31. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Gulkas S; Sahin O Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613 [TBL] [Abstract][Full Text] [Related]
32. Utility of an additional photodynamic therapy session after multiple failed PDT treatments in chronic central serous chorioretinopathy. Moreno-Morillo FJ; Fernández-Vigo JI; Burgos-Blasco B; Moriche-Carretero M; López-Guajardo L; Donate-López J Photodiagnosis Photodyn Ther; 2022 Sep; 39():102953. PubMed ID: 35690322 [TBL] [Abstract][Full Text] [Related]
33. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Rouvas A; Stavrakas P; Theodossiadis PG; Stamatiou P; Milia M; Giannakaki E; Datseris I Eur J Ophthalmol; 2012; 22(3):417-22. PubMed ID: 21928269 [TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study. Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971 [TBL] [Abstract][Full Text] [Related]
35. Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy. Copete S; Ruiz-Moreno JM; Cava C; Montero JA Graefes Arch Clin Exp Ophthalmol; 2012 Jun; 250(6):803-8. PubMed ID: 22222922 [TBL] [Abstract][Full Text] [Related]
36. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251 [TBL] [Abstract][Full Text] [Related]
37. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105 [TBL] [Abstract][Full Text] [Related]
38. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
39. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases. Donati MC; Miele A; Abbruzzese G; Giuntoli M; Giansanti F; Menchini U Eur J Ophthalmol; 2013; 23(2):267-70. PubMed ID: 23225087 [TBL] [Abstract][Full Text] [Related]
40. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy]. Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]